Investigational drug · Phase 3
Verducatib
Also called: BI 1291583
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchiectasis, Chronic Obstructive Pulmonary Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
20
Any phase or sponsor naming "Verducatib"
First trial start
2023
Sep 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Verducatib", any sponsor or status.
- Phase 114
Conditions studied
As listed on its trial records.
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Verducatib" as an intervention, largest first.
- The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07907991 · 1,800 participants (planned) · Start Mar 10, 2027 · Primary completion Nov 12, 2029
Drug: Verducatib; Placebo matching verducatib · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; La Palma, California · 26 sites in all
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06872892 · 1,755 participants (planned) · Start Jun 9, 2025 · Primary completion Jun 15, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 474 sites in all
- A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Pivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07915219 · 1,500 participants (planned) · Start Jan 11, 2027 · Primary completion Jul 31, 2029
Drug: verducatib · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 394 sites in all
- A Study to Test Whether Different Doses of BI 1291583 Help People With BronchiectasisPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05238675 · 322 participants · Start Apr 28, 2022 · Primary completion May 1, 2024
Drug: BI 1291583; Placebo · For: Bronchiectasis
Sites: Peoria, Arizona; Newport Beach, California; Sacramento, California · 112 sites in all
- Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicinePivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05846230 · 268 participants · Start Sep 8, 2023 · Primary completion Mar 31, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Newport Beach, California; Sacramento, California; Gainesville, Florida · 103 sites in all
- A Study in Healthy People to Measure How Different Doses of Verducatib Affect the HeartActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07760246 · 56 participants · Start Aug 20, 2026 · Primary completion Dec 30, 2026
Drug: Verducatib; Moxifloxacin and 2 more · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT03414008 · 54 participants · Start Feb 5, 2018 · Primary completion Nov 18, 2019
Drug: BI 1291583; Matching placebo: Tartaric acid · For: Healthy
Sites: Biberach, Germany
- A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are ToleratedCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05183347 · 36 participants · Start Feb 4, 2022 · Primary completion Jul 27, 2022
Drug: BI 1291583; Placebo · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
- A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07023354 · 32 participants (planned) · Start Jul 17, 2025 · Primary completion Dec 23, 2026
Drug: BI 1291583 · For: Healthy; Hepatic Impairment
Sites: Rialto, California; Orlando, Florida; Houston, Texas · 4 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06631417 · 30 participants · Start Oct 22, 2024 · Primary completion Jan 10, 2025
Drug: BI 1291583; BI 1291583 and 1 more · For: Healthy
Sites: Biberach, Germany
Newest research
PubMed records naming it or its code names, newest first.
- The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.
Chalmers JD, Jain R, O'Donnell AE, et al. · Eur Respir Rev 2026
- Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.
Chalmers JD, Shteinberg M, Chotirmall SH, et al. · ERJ Open Res 2026
- Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors.
Premuda C, Gramegna A, Misuraca S, et al. · Expert Opin Pharmacother 2026
- Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.
Flume PA, Maselli DJ · Pulm Ther 2026
- Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
Zhang D, Zhang W, Hu P, et al. · Front Pharmacol 2025
- Dipeptidyl peptidase 1 inhibitors and neutrophilic inflammation in bronchiectasis: a narrative review.
Tang RD, Yue JQ, Chalmers JD, et al. · J Thorac Dis 2025
Also in development for Bronchiectasis
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- CHF10196florensocatibPhase 31 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
- GSK3862995BPhase 22 trials
GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive
- CHF6333Phase 21 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.